vs
EXACT SCIENCES CORP（EXAS）与朗美通（LITE）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是朗美通的1.3倍（$878.4M vs $665.5M），朗美通净利率更高（11.8% vs -9.8%，领先21.5%），朗美通同比增速更快（65.5% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $43.1M），过去两年朗美通的营收复合增速更高（34.8% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
朗美通控股（Lumentum Holdings Inc.）是全球知名光电产品供应商，前身为美国捷迪讯（JDSU）旗下光电器件及激光业务板块，2015年8月随捷迪讯分拆独立运营，总部位于美国加利福尼亚州米尔皮塔斯，主营光通信网络设备、激光器、定制光学解决方案等多元产品。
EXAS vs LITE — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$665.5M
营收增速更快
LITE
高出42.3%
23.1%
净利率更高
LITE
高出21.5%
-9.8%
自由现金流更多
EXAS
多$77.3M
$43.1M
两年增速更快
LITE
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $665.5M |
| 净利润 | $-86.0M | $78.2M |
| 毛利率 | 70.1% | 36.1% |
| 营业利润率 | -9.4% | 9.7% |
| 净利率 | -9.8% | 11.8% |
| 营收同比 | 23.1% | 65.5% |
| 净利润同比 | 90.1% | 228.4% |
| 每股收益（稀释后） | $-0.45 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASLITE
| Q4 25 | $878.4M | $665.5M | ||
| Q3 25 | $850.7M | $533.8M | ||
| Q2 25 | $811.1M | $480.7M | ||
| Q1 25 | $706.8M | $425.2M | ||
| Q4 24 | $713.4M | $402.2M | ||
| Q3 24 | $708.7M | $336.9M | ||
| Q2 24 | $699.3M | $308.3M | ||
| Q1 24 | $637.5M | $366.5M |
净利润EXASLITE
| Q4 25 | $-86.0M | $78.2M | ||
| Q3 25 | $-19.6M | $4.2M | ||
| Q2 25 | $-1.2M | $213.3M | ||
| Q1 25 | $-101.2M | $-44.1M | ||
| Q4 24 | $-864.6M | $-60.9M | ||
| Q3 24 | $-38.2M | $-82.4M | ||
| Q2 24 | $-15.8M | $-252.5M | ||
| Q1 24 | $-110.2M | $-127.0M |
毛利率EXASLITE
| Q4 25 | 70.1% | 36.1% | ||
| Q3 25 | 68.6% | 34.0% | ||
| Q2 25 | 69.3% | 33.3% | ||
| Q1 25 | 70.8% | 28.8% | ||
| Q4 24 | 69.0% | 24.8% | ||
| Q3 24 | 69.4% | 23.1% | ||
| Q2 24 | 69.8% | 16.6% | ||
| Q1 24 | 70.0% | 16.2% |
营业利润率EXASLITE
| Q4 25 | -9.4% | 9.7% | ||
| Q3 25 | -3.0% | 1.3% | ||
| Q2 25 | -0.3% | -1.7% | ||
| Q1 25 | -13.6% | -8.9% | ||
| Q4 24 | -122.8% | -12.8% | ||
| Q3 24 | -5.6% | -24.5% | ||
| Q2 24 | -3.8% | -43.3% | ||
| Q1 24 | -16.7% | -31.3% |
净利率EXASLITE
| Q4 25 | -9.8% | 11.8% | ||
| Q3 25 | -2.3% | 0.8% | ||
| Q2 25 | -0.1% | 44.4% | ||
| Q1 25 | -14.3% | -10.4% | ||
| Q4 24 | -121.2% | -15.1% | ||
| Q3 24 | -5.4% | -24.5% | ||
| Q2 24 | -2.3% | -81.9% | ||
| Q1 24 | -17.3% | -34.7% |
每股收益（稀释后）EXASLITE
| Q4 25 | $-0.45 | $0.89 | ||
| Q3 25 | $-0.10 | $0.05 | ||
| Q2 25 | $-0.01 | $3.10 | ||
| Q1 25 | $-0.54 | $-0.64 | ||
| Q4 24 | $-4.69 | $-0.88 | ||
| Q3 24 | $-0.21 | $-1.21 | ||
| Q2 24 | $-0.09 | $-3.75 | ||
| Q1 24 | $-0.60 | $-1.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.2B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $846.6M |
| 总资产 | $5.9B | $4.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASLITE
| Q4 25 | $964.7M | $1.2B | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | $858.4M | $877.1M | ||
| Q1 25 | $786.2M | $866.7M | ||
| Q4 24 | $1.0B | $896.7M | ||
| Q3 24 | $1.0B | $916.1M | ||
| Q2 24 | $946.8M | $887.0M | ||
| Q1 24 | $652.1M | $870.9M |
股东权益EXASLITE
| Q4 25 | $2.4B | $846.6M | ||
| Q3 25 | $2.5B | $780.8M | ||
| Q2 25 | $2.5B | $1.1B | ||
| Q1 25 | $2.4B | $879.5M | ||
| Q4 24 | $2.4B | $872.3M | ||
| Q3 24 | $3.2B | $895.9M | ||
| Q2 24 | $3.2B | $957.3M | ||
| Q1 24 | $3.1B | $1.2B |
总资产EXASLITE
| Q4 25 | $5.9B | $4.8B | ||
| Q3 25 | $5.9B | $4.6B | ||
| Q2 25 | $5.8B | $4.2B | ||
| Q1 25 | $5.7B | $4.0B | ||
| Q4 24 | $5.9B | $4.0B | ||
| Q3 24 | $6.7B | $4.0B | ||
| Q2 24 | $6.7B | $3.9B | ||
| Q1 24 | $6.4B | $4.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $126.7M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $43.1M |
| 自由现金流率自由现金流/营收 | 13.7% | 6.5% |
| 资本支出强度资本支出/营收 | 3.6% | 12.6% |
| 现金转化率经营现金流/净利润 | — | 1.62× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $-29.5M |
8季度趋势，按日历期对齐
经营现金流EXASLITE
| Q4 25 | $151.7M | $126.7M | ||
| Q3 25 | $219.9M | $57.9M | ||
| Q2 25 | $89.0M | $64.0M | ||
| Q1 25 | $30.8M | $-1.6M | ||
| Q4 24 | $47.1M | $24.3M | ||
| Q3 24 | $138.7M | $39.6M | ||
| Q2 24 | $107.1M | $35.5M | ||
| Q1 24 | $-82.3M | $-7.0M |
自由现金流EXASLITE
| Q4 25 | $120.4M | $43.1M | ||
| Q3 25 | $190.0M | $-18.3M | ||
| Q2 25 | $46.7M | $10.1M | ||
| Q1 25 | $-365.0K | $-64.4M | ||
| Q4 24 | $10.7M | $-15.9M | ||
| Q3 24 | $112.6M | $-34.5M | ||
| Q2 24 | $71.2M | $10.9M | ||
| Q1 24 | $-120.0M | $-26.6M |
自由现金流率EXASLITE
| Q4 25 | 13.7% | 6.5% | ||
| Q3 25 | 22.3% | -3.4% | ||
| Q2 25 | 5.8% | 2.1% | ||
| Q1 25 | -0.1% | -15.1% | ||
| Q4 24 | 1.5% | -4.0% | ||
| Q3 24 | 15.9% | -10.2% | ||
| Q2 24 | 10.2% | 3.5% | ||
| Q1 24 | -18.8% | -7.3% |
资本支出强度EXASLITE
| Q4 25 | 3.6% | 12.6% | ||
| Q3 25 | 3.5% | 14.3% | ||
| Q2 25 | 5.2% | 11.2% | ||
| Q1 25 | 4.4% | 14.8% | ||
| Q4 24 | 5.1% | 10.0% | ||
| Q3 24 | 3.7% | 22.0% | ||
| Q2 24 | 5.1% | 8.0% | ||
| Q1 24 | 5.9% | 5.3% |
现金转化率EXASLITE
| Q4 25 | — | 1.62× | ||
| Q3 25 | — | 13.79× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
LITE
| Components | $443.7M | 67% |
| Systems | $221.8M | 33% |
